



## Eagle Pharmaceuticals Announces Commencement of Public Offering of Common Stock

March 16, 2015

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell approximately \$50,000,000 of shares of its common stock. In addition, certain stockholders of the Company (the "Selling Stockholders") are offering 129,800 shares of the Company's common stock for sale to the public. In connection with the offering, Eagle expects that the underwriters will be granted a 30-day option to purchase from Eagle up to an additional 15% of the shares offered by Eagle and the Selling Stockholders. Eagle will not receive any proceeds from the sale of the shares by the selling stockholders, and Eagle intends to use the net proceeds received from its offering of common stock for general corporate purposes. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Piper Jaffray & Co., William Blair & Company, L.L.C. and RBC Capital Markets, LLC, are acting as book-running managers for the offering. Cantor Fitzgerald & Co. is acting as a co-manager.

The securities described above are being offered pursuant to a shelf registration statement previously filed with the Securities Exchange Commission (the "SEC") on March 6, 2015, and declared effective by the SEC on March 13, 2015. A final prospectus supplement relating to the offering will be filed with the SEC and available for free on the SEC's website at <http://www.sec.gov>. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from Piper Jaffray at 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, at Attention: Prospectus Department, or by calling (800) 747-3924, or by emailing [prospectus@pic.com](mailto:prospectus@pic.com); or from William Blair & Company, L.L.C. at Attention: Prospectus Department, 222 West Adams Street, Chicago, IL 60606, or by calling (800) 621-0687, or by emailing [prospectus@williamblair.com](mailto:prospectus@williamblair.com); or from RBC Capital Markets, Attention: Prospectus Department, 200 Vesey Street 8th Floor, New York, NY 10281, or by calling (877) 822-4089, or by emailing [equityprospectus@rbccm.com](mailto:equityprospectus@rbccm.com).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

### About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. The Company's strategy is to utilize the FDA's 505(b)(2) regulatory pathway.

### Forward-Looking Statements

Statements in this press release regarding matters that are not historical facts, including expectations regarding the completion and timing of Eagle's proposed public offering, are forward-looking statements. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as other risks and uncertainties described in Eagle's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in Eagle's Annual Report on Form 10-K for the year ended September 30, 2014 and subsequent filings with the SEC. You are encouraged to read Eagle's filings with the SEC, available at [www.sec.gov](http://www.sec.gov), for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this press release, and Eagle undertakes no obligation to update or revise any of the statements.

In-Site Communications, Inc.  
Lisa M. Wilson, 212-452-2793  
President